Scientist, Structural Biology / Biochemistry
Flagship Pioneering, Inc.
Summary
FL132 is seeking a detail-oriented and highly collaborative Scientist I/II (level TBD based on experience) to help build our amyloid research platform from the ground up. Working closely with the Principal Scientist leading protein biophysics and structural characterization, this is a hands-on bench role centered on producing and qualifying assay-grade amyloid proteins, executing quantitative aggregation assays, and supporting the development of cell-based models of amyloid toxicity, seeding, and clearance. This is an on-site, bench-based position in Cambridge, MA.
Job description
Position Summary
FL132 is seeking a detail-oriented and highly collaborative Scientist I/II (level TBD based on experience) to help build our amyloid research platform from the ground up. Working closely with the Principal Scientist leading protein biophysics and structural characterization, this is a hands-on bench role centered on producing and qualifying assay-grade amyloid proteins, executing quantitative aggregation assays, and supporting the development of cell-based models of amyloid toxicity, seeding, and clearance. This is an on-site, bench-based position in Cambridge, MA.
Key Responsibilities
- Execute recombinant amyloid protein production and quality control, including expression, purification, and seed-free monomer preparation
- Run plate-based amyloid aggregation assays, e.g., ThT and related kinetic readouts
- Analyze and present experimental data, generating clean, well-annotated datasets and contributing to kinetic analysis and fitting
- Support structural and biochemical characterization of amyloid aggregates, preparing samples and assisting with mass spectrometry, cryo-EM, or related measurements
- Maintain mammalian cell and tissue culture in support of assays for amyloid toxicity, seeding, and clearance
- Contribute to assay development and technical troubleshooting
- Maintain rigorous, timely documentation in the electronic lab notebook and help establish shared protocols
- Support general laboratory operations, including reagent and inventory management, equipment maintenance and qualification, and laboratory safety practices
- Collaborate across the team and with external partners, communicating results and issues clearly
Required Qualifications
- BA/BS (10+ yrs), MA/MS (8+ yrs), or PhD (0-2 yrs) in biology, chemistry, biophysics, or a related field, with relevant research experience
- Direct, hands-on experience with conducting plate-based assays and cell/tissue culture
- Experience with recombinant protein expression and purification (e.g., bacterial expression, FPLC/ÄKTA chromatography, SDS-PAGE, size-exclusion chromatography)
- Ability to work precisely and reproducibly on repetitive, high-care protocols
- Strong written/verbal communication, collaboration, and problem-solving skills
- Proficiency analyzing and plotting experimental data in Python, R, GraphPad Prism, or equivalent is a plus
Preferred Qualifications
- Experience with kinetic assays of protein aggregation (e.g., ThT fluorescence); familiarity with global kinetic fitting of aggregation data
- Demonstrated experience with technical troubleshooting and systematic assay optimization
- Experience with cell-based assays relevant to protein aggregation, such as viability and toxicity readouts, fluorescence microscopy, flow cytometry, or FRET-based seeding assays
- Experience preparing samples for, or working alongside, structural and biophysical characterization methods: mass spectrometry (e.g., LiP-MS), or cryo-EM
- Familiarity with amyloid aggregation mechanisms, strain and seeding biology, cofactor and inducer systems, or neurodegenerative disease biology
Requirements
- BA/BS (10+ yrs), MA/MS (8+ yrs), or PhD (0-2 yrs) in biology, chemistry, biophysics, or a related field
- Direct, hands-on experience with conducting plate-based assays and cell/tissue culture
- Experience with recombinant protein expression and purification (e.g., bacterial expression, FPLC/ÄKTA chromatography, SDS-PAGE, size-exclusion chromatography)
- Ability to work precisely and reproducibly on repetitive, high-care protocols
- Commitment to laboratory safety, detailed documentation, and data integrity
- Strong written/verbal communication, collaboration, and problem-solving skills
- Proficiency analyzing and plotting experimental data in Python, R, GraphPad Prism, or equivalent is a plus
- Experience with kinetic assays of protein aggregation (e.g., ThT fluorescence)
- Familiarity with global kinetic fitting of aggregation data
- Demonstrated experience with technical troubleshooting and systematic assay optimization
- Experience with cell-based assays relevant to protein aggregation
- Experience preparing samples for structural and biophysical characterization methods: mass spectrometry or cryo-EM
- Familiarity with amyloid aggregation mechanisms, strain and seeding biology, cofactor and inducer systems, or neurodegenerative disease biology
Benefits
- Healthcare coverage
- Annual incentive program
- Retirement benefits
- Free snacks and coffee
- Monthly social events
Company overview
Flagship Pioneering is a pioneering biotechnology venture capital firm that specializes in conceiving, creating, and developing first-in-category life sciences companies. Founded in 2000 and headquartered in Cambridge, Massachusetts, the firm applies a unique hypothesis-driven innovation process to originate and foster scientific ventures with transformative potential for human health and sustainability. Flagship has originated over 100 scientific ventures since its inception, creating more than $30 billion in aggregate value across its portfolio. The firm's ecosystem includes notable companies such as Moderna Therapeutics, Denali Therapeutics, Evelo Biosciences, and Seres Therapeutics, among others. Flagship operates through a systematic entrepreneurship model that combines scientific creativity, technological ingenuity, and executive leadership to build platform companies capable of generating multiple breakthrough products. With over $3 billion in aggregate capital commitments, the firm invests primarily in therapeutics, health technologies, and sustainability sectors, working in partnership with academic institutions, pharmaceutical companies, and investment communities to advance groundbreaking science and innovation globally.